GSK’s Zejula Wins First-Line Ovarian Cancer Use
FDA Extension Is PARP Inhibitor’s Third Indication In That Disease
Winning an expanded US FDA indication for Zejula as a first-line ovarian cancer treatment further vindicates GSK’s hefty purchase price for Tesaro and sets the scene for more therapeutic extensions for the PARP inhibitor, oncology R&D chief Axel Hoos told Scrip.
